Cencora Inc.

11/04/2026 | Press release | Distributed by Public on 11/04/2026 08:25

CENCORA, INC. SUMMARY REPORTABLE SEGMENT INFORMATION (Form 8-K)

CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)
The following illustrates revised reportable segment revenue information for the periods indicated:
Fiscal Year Ended September 30, 2026
Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year
(As Revised) (As Revised) (As Revised) (As Revised) (As Revised)
Pharmaceutical Distribution and Services $ 72,969,277 $ 66,108,390 $ 71,164,265 $ 74,242,224 $ 284,484,156
Specialty Pharmaceutical and Provider Services 11,098,508 10,471,417 11,645,430 12,175,177 45,390,532
Other 2,128,947 2,055,571 2,253,330 2,302,073 8,739,921
Intersegment eliminations (264,716) (279,462) (308,188) (364,944) (1,217,310)
Total revenue $ 85,932,016 $ 78,355,916 $ 84,754,837 $ 88,354,530 $ 337,397,299
Fiscal Year Ended September 30, 2025
Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year
(As Revised) (As Revised) (As Revised) (As Revised) (As Revised)
Pharmaceutical Distribution and Services $ 69,441,734 $ 63,350,601 $ 67,700,658 $ 71,352,299 $ 271,845,292
Specialty Pharmaceutical and Provider Services 10,490,286 10,418,900 11,136,471 10,542,389 42,588,046
Other 2,002,455 1,956,407 2,107,464 2,091,507 8,157,833
Intersegment eliminations (447,415) (272,235) (281,061) (257,641) (1,258,352)
Total revenue $ 81,487,060 $ 75,453,673 $ 80,663,532 $ 83,728,554 $ 321,332,819
CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)
The following illustrates revised reportable segment operating income and margin information for the periods indicated:
Fiscal Year Ended September 30, 2026
Operating income First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year
(As Revised) (As Revised) (As Revised) (As Revised) (As Revised)
Pharmaceutical Distribution and Services $ 606,904 $ 774,786 $ 664,122 $ 690,546 $ 2,736,358
Specialty Pharmaceutical and Provider Services 366,582 399,311 467,908 459,221 1,693,022
Other 91,417 91,633 108,736 101,075 392,861
Intersegment eliminations (2,189) (2,381) (2,680) (1,944) (9,194)
Total segment operating income $ 1,062,714 $ 1,263,349 $ 1,238,086 $ 1,248,898 $ 4,813,047
Percentages of revenue:
Pharmaceutical Distribution and Services
Gross profit 2.26% 2.70% 2.39% 2.31% 2.41%
Operating expenses 1.43% 1.52% 1.45% 1.38% 1.45%
Operating income 0.83% 1.17% 0.93% 0.93% 0.96%
Specialty Pharmaceutical and Provider Services
Gross profit 9.21% 12.27% 12.89% 12.58% 11.76%
Operating expenses 5.91% 8.45% 8.88% 8.81% 8.03%
Operating income 3.30% 3.81% 4.02% 3.77% 3.73%
Other
Gross profit 15.24% 15.16% 14.58% 14.30% 14.81%
Operating expenses 10.95% 10.70% 9.76% 9.91% 10.31%
Operating income 4.29% 4.46% 4.83% 4.39% 4.50%
CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)
Fiscal Year Ended September 30, 2025
Operating income First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year
(As Revised) (As Revised) (As Revised) (As Revised) (As Revised)
Pharmaceutical Distribution and Services $ 569,446 $ 725,639 $ 590,995 $ 614,651 $ 2,500,731
Specialty Pharmaceutical and Provider Services 282,531 373,741 380,246 333,989 1,370,507
Other 97,329 92,851 87,104 74,429 351,713
Intersegment eliminations 2 33 (14) 1 22
Total segment operating income $ 949,308 $ 1,192,264 $ 1,058,331 $ 1,023,070 $ 4,222,973
Percentages of revenue:
Pharmaceutical Distribution and Services
Gross profit 2.27% 2.62% 2.33% 2.28% 2.37%
Operating expenses 1.45% 1.47% 1.46% 1.42% 1.45%
Operating income 0.82% 1.15% 0.87% 0.86% 0.92%
Specialty Pharmaceutical and Provider Services
Gross profit 6.14% 9.01% 8.67% 9.23% 8.27%
Operating expenses 3.44% 5.42% 5.26% 6.07% 5.05%
Operating income 2.69% 3.59% 3.41% 3.17% 3.22%
Other
Gross profit 15.86% 16.27% 14.95% 14.57% 15.40%
Operating expenses 11.00% 11.53% 10.82% 11.01% 11.08%
Operating income 4.86% 4.75% 4.13% 3.56% 4.31%
Cencora Inc. published this content on November 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 04, 2026 at 14:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]